The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Associations of Serum Osteoprotegerin Levels with Diabetes, Stroke, Bone Density, Fractures, and Mortality in Elderly Women1
Open accessAbstract
Osteoprotegerin (OPG) and its ligand are cytokines that regulate osteoclastogenesis and that may be involved in the regulation of vascular calcification. We examined whether serum OPG levels were associated with stroke, mortality, and cardiovascular risk factors, including diabetes, as well as with bone mineral density and fractures in a sample of 490 participants in a prospective cohort of white women, at least 65 yr of age. We found that OPG levels, assayed blinded from serum obtained at baseline, were about 30% greater in women with diabetes (mean ± sd, 0.30 ± 0.17 ng/mL) than in those without diabetes (0.23 ± 0.10 ng/mL; P= 0.0001). OPG levels were associated with all-cause mortality[ age-adjusted odds ratio, 1.4/sd (0.11 ng/mL) increase in serum OPG level; 95% confidence interval, 1.2–1.8] and cardiovascular mortality (odds ratio, 1.4; 95% confidence interval, 1.1–1.8); these effects were not confounded by diabetes. OPG levels were not associated with baseline bone mineral density or with subsequent strokes or fractures. The association of serum OPG levels with diabetes and with cardiovascular mortality raises the possibility that OPG may be a cause of or a marker for vascular calcification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein
Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., & Karsenty, G. (1997) · Nature · doi:10.1038/386078a0 · Cited by 2,120
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis
Stern, M. P. (1995) · Diabetes · doi:10.2337/diab.44.4.369 · Cited by 739
Cited by
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Changes in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 914
Vascular Calcification: Mechanisms and Clinical Ramifications
Abedin, M., Tintut, Y., & Demer, L. L. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000133194.94939.42 · Cited by 863
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease
Kiechl, S., Schett, G., Wenning, G., Redlich, K., Oberhollenzer, M., Mayr, A., Santer, P., Smolen, J., Poewe, W., & Willeit, J. (2004) · Circulation · doi:10.1161/01.cir.0000127957.43874.bb · Cited by 505
Jono, S., Ikari, Y., Shioi, A., Mori, K., Miki, T., Hara, K., & Nishizawa, Y. (2002) · Circulation · doi:10.1161/01.cir.0000031524.49139.29 · Cited by 489
RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 405
Osteogenic regulation of vascular calcification: an early perspective
Vattikuti, R., & Towler, D. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00552.2003 · Cited by 397
Candidate‐based proteomics in the search for biomarkers of cardiovascular disease
Anderson, L. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.080473 · Cited by 378
The role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
Bone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 347
Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease
Schoppet, M., Sattler, A. M., Schaefer, J. R., Herzum, M., Maisch, B., & Hofbauer, L. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020775 · Cited by 324
Tanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
Osteoprotegerin, vascular calcification and atherosclerosis
Van Campenhout, A., & Golledge, J. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.033 · Cited by 308
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Doherty, T. M., Fitzpatrick, L. A., Inoue, D., Qiao, J.-H., Fishbein, M. C., Detrano, R. C., Shah, P. K., & Rajavashisth, T. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0015 · Cited by 299
Osteoporosis and Cardiovascular Disease: Brittle Bones and Boned Arteries, Is There a Link?
McFarlane, S. I., Muniyappa, R., Shin, J. J., Bahtiyar, G., & Sowers, J. R. (2004) · Endocrine · doi:10.1385/endo:23:1:01 · Cited by 289
Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr (−/−) Mice
Morony, S., Tintut, Y., Zhang, Z., Cattley, R. C., Van, G., Dwyer, D., Stolina, M., Kostenuik, P. J., & Demer, L. L. (2008) · Circulation · doi:10.1161/circulationaha.107.707380 · Cited by 258
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Correlates of osteoprotegerin levels in women and men.
Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205
Rogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200
“(18), there was no relationship between OPG and bone density.”
BackgroundSerum levels of osteoprotegerin increase with age in a healthy adult population.
Kudlacek, S., Schneider, B., Woloszczuk, W., Pietschmann, P., & Willvonseder, R. (2003) · Bone · doi:10.1016/s8756-3282(03)00090-5 · Cited by 187
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao, J., Venton, L., Sakata, T., & Halloran, B. P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.270 · Cited by 173
Morabito, N., Gaudio, A., Lasco, A., Atteritano, M., Pizzoleo, M. A., Cincotta, M., La Rosa, M., Guarino, R., Meo, A., & Frisina, N. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040113 · Cited by 127
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
Indridason, O. S., Franzson, L., & Sigurdsson, G. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1699-x · Cited by 107
Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1844-1 · Cited by 98
J�rgensen, H. L., Kusk, P., Madsen, B., Fenger, M., & Lauritzen, J. B. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0461-3 · Cited by 85
Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76
Dobnig, H., Hofbauer, L. C., Viereck, V., Obermayer-Pietsch, B., & Fahrleitner-Pammer, A. (2006) · Osteoporosis International · doi:10.1007/s00198-005-0035-4 · Cited by 76
Oh, K. W., Rhee, E. J., Lee, W. Y., Kim, S. W., Baek, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Ihm, S. H., Choi, M. G., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02179.x · Cited by 73
Fahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71
Alvarez, L., Peris, P., Guañabens, N., Vidal, S., Ros, I., Pons, F., Filella, X., Monegal, A., Muñoz‐Gomez, J., & Ballesta, A. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10834 · Cited by 66
Fahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62
Oh, E. S., Rhee, E.-J., Oh, K. W., Lee, W. Y., Baek, K. H., Yoon, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Choi, M. G., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.005 · Cited by 61
Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures
Abdallah, B. M., Stilgren, L. S., Nissen, N., Kassem, M., Jørgensen, H. R. I., & Abrahamsen, B. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0074-4 · Cited by 60
Tschiderer, L., Willeit, J., Schett, G., Kiechl, S., & Willeit, P. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183910 · Cited by 45
Han, K. O., Choi, J. T., Choi, H. A., Moon, I. G., Yim, C. H., Park, W. K., Yoon, H. K., & Han, I. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02221.x · Cited by 32
Uemura, H., Yasui, T., Umino, Y., Niki, H., Takikawa, M., Saito, S., Furumoto, H., & Irahara, M. (2003) · Bone · doi:10.1016/j.bone.2003.08.001 · Cited by 7
Gaudio, A., Muratore, F., Fiore, V., Rapisarda, R., Signorelli, S. S., & Fiore, C. E. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3057-6 · Cited by 6
Metadata
- Authors
- Browner, W. S., Lui, L.-Y., & Cummings, S. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-02-01
- Volume
- 86
- Issue
- 2
- Pages
- 631-637
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2128791904
- Cited by
- 506
- References
- 33
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.